Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Taiho Oncology, Inc.
Taiho Oncology, Inc.
Adela, Inc
OncoNano Medicine, Inc.
Incyte Corporation
Incyte Corporation
Novartis
Tempus AI
RAPT Therapeutics, Inc.
VitaMed Research LLC
ModernaTX, Inc.
Sanguine Biosciences
Stingthera, Inc.
Fate Therapeutics
Fate Therapeutics
Blue Note Therapeutics
Incyte Corporation
AstraZeneca
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
MultiVir, Inc.
Celgene
Tocagen Inc.
Shenzhen BinDeBio Ltd.
Novartis
GlaxoSmithKline
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Amgen
Valerio Therapeutics
Altor BioScience
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.